2. Search Result
Search Result
Results for "

CPT 11

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16562
    Irinotecan
    Maximum Cited Publications
    50 Publications Verification

    (+)-Irinotecan; CPT-11; VAL-413(free base)

    		 Topoisomerase Autophagy Cancer
    Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan
  • HY-16562A
    Irinotecan hydrochloride
    Maximum Cited Publications
    50 Publications Verification

    (+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan hydrochloride
  • HY-16568
    Irinotecan hydrochloride trihydrate
    Maximum Cited Publications
    50 Publications Verification

    (+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
    Irinotecan hydrochloride trihydrate
  • HY-16562S
    Irinotecan-d10

    (+)-Irinotecan-d10; CPT-11-d10; VAL-413-d10

    		 Topoisomerase Autophagy Cancer
    Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].
    Irinotecan-d10
  • HY-100620
    RPR121056

    APC

    		 Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE .
    RPR121056
  • HY-100638A
    RPR132595A hydrochloride

    NPC hydrochloride

    		 Drug Metabolite Cancer
    RPR132595A (NPC) hydrochloride is an active metabolite of CPT-11, which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine .
    RPR132595A hydrochloride
  • HY-16562AS
    Irinotecan-d5 hydrochloride

    (+)-Irinotecan-d5 hydrochloride; CPT-11-d5 hydrochloride; VAL-413-d5

    		 Autophagy Topoisomerase Isotope-Labeled Compounds Cancer
    Irinotecan-d5 hydrochloride is deuterated labeled Irinotecan hydrochloride (HY-16562A). Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan-d5 hydrochloride
  • HY-100620R
    RPR121056 (Standard)

    APC (Standard)

    		 Drug Metabolite Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (Standard) is the analytical standard of RPR121056. This product is intended for research and analytical applications. RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1].
    RPR121056 (Standard)
  • HY-149291
    ATM Inhibitor-7

    		ATM/ATR Apoptosis Cancer
    ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC50 value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity .
    ATM Inhibitor-7
  • HY-100638
    RPR132595A

    NPC

    		 Drug Metabolite Cancer
    RPR132595A (NPC) is an active metabolite of CPT-11, which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine .
    RPR132595A
  • HY-145513
    CL2-MMT-SN38

    		Topoisomerase Cancer
    CL2-MMT-SN38 is a SN-38 derivative. SN-38, an anticancer agent, is an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11) .
    CL2-MMT-SN38
  • HY-120638
    BMS-250749

    		Topoisomerase Cancer
    BMS-250749 is a topoisomerase I (Top I) inhibitor of the fluoroglycosyl-3,9-difluoroindolecarbazole class. BMS-250749 exhibits potent cytotoxicity and selectivity, and shows curative antitumor activity against Lewis lung cancer. BMS-250749 exhibits broad-spectrum antitumor activity superior to CPT-11 in certain preclinical xenograft models. .
    BMS-250749